Monarch Partners Asset Management LLC Buy nearly 5,000 Shares in ANI Pharmaceuticals

As stated by Monarch Partners Asset Management LLC in its latest Form 13F filing with the U.S. Securities and Exchange Commission, in the first quarter, the company purchased a new stake in ANI Pharmaceuticals.ANI Pharmaceuticals’ 5,100 shares were purchased by an institutional investor. These shares are known to be worth nearly $360,000.

Recently, numerous other large-scale investors adjusted their shares in the pharmaceutical company. In the third quarter, MetLife Investment Advisors LLC increased its ANI Pharmaceuticals’ holdings by 55.6%. Following the purchase of further 2,195 ANI Pharmaceutical shares in the last quarter, the MetLife Investment Advisors LLC is now owner to 6,140 ANI Pharmaceutical shares which are worth a total of $347,000.In the third quarter, AQR Capital Management LLC increased its ANI Pharmaceuticals’ holdings by 21.9%. Following the purchase of further 1,757 ANI Pharmaceutical shares in the last quarter, the AQR Capital Management LLC is now owner to 9,792 ANI Pharmaceutical shares which are worth a total of $554,000. Also in the third quarter, TIAA CREF Investment Management LLC increased its ANI Pharmaceuticals’ holdings by 5.7%. Following the purchase of further 2,635 ANI Pharmaceutical shares in the last quarter, the TIAA CREF Investment Management LLC is now owner to 48,667 ANI Pharmaceutical shares which are worth$2,752,000. Lastly, in the second-last quarter, Vanguard Group Inc. increased its ANI Pharmaceuticals’ holdings by 1.6%. Following the purchase of further 8,173 ANI Pharmaceutical shares in the last quarter, the Vanguard Group Inc. is now owner to 522,813 ANI Pharmaceutical shares which are worth a total of $29,559,000.63.92% of ANI Pharmaceutical’s stock is owned by an institutional investor.

It was also reported, on the 24th of May, how ANI Pharmaceuticals’ Director David Nash purchased 1,445 shares of the stock, bought at the mean cost of $68.76 per each share, making up a total of $99,358.20. David Nash is now owner to 5,236 shares of ANI Pharmaceuticals’ stocks, worth $360,027.36.